Biocorp and BD partner in connected drug delivery devices

(AOF) – Biocorp, a French company specializing in the development and manufacture of medical devices and drug delivery systems, and BD announce that they have signed an agreement to use connected technology to monitor treatment compliance self-administered drugs. They will explore the possibilities of combining Biocorp’s Injay® technology with the BD UltraSafePlusTM passive needle guard to help biopharmaceutical manufacturers capture and transmit data related to self-administered injections.

Aimed to support biopharmaceutical companies in their efforts to improve adherence to injectable treatment, the two companies will integrate Biocorp’s Injay® technology – a solution designed to capture and transmit injection data to using Near Field Communication (NFC) technology – the BD UltraSafe Plus™ Passive Needle Guard System used with prefilled syringes.

“We are combining Biocorp’s expertise in the development and commercialization of connected drug delivery devices with our existing portfolio of advanced injection drug delivery systems,” said Matthew Schabacker, vice president and general manager. of Advanced Drug Delivery Solutions at BD.

Biocorp’s Injay® device is a simple and cost-effective connected solution designed to track the use of pre-filled syringes in clinical studies or routine care. Using NFC technology and specific sensors to identify the product, it can confirm a complete injection and automatically transfer this information to a smartphone.

The global connected medication delivery market is expected to experience double-digit growth rates over the next decade – fueled by the shift from healthcare facilities to home care and the increased prevalence of self-administered therapies.


The AOF information reproduced on is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors in no way guarantee the absence of error and defects, even hidden ones, nor the exhaustive character or the lack of conformity for any use whatsoever of this data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.

Leave a Comment